 LADENBURG THALMSH SH reaffirmed their buy rating on shares of Checkpoint Therapeutics NASDAQ:CKPT in a report published on Wednesday, AnalystRatings.com reports. The brokerage currently has a 20.00 price objective on the stock. Separately, HC Wainwright reissued a buy rating and issued a 15.00 price target on shares of Checkpoint Therapeutics in a research report on ... 